Inpatient hospital burden of hepatitis C-diagnosed patients with decompensated cirrhosis
Related Experiment Video
Updated: Feb 16, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
Scott A McDonald1,2, Hamish A Innes1,2, Esther J Aspinall1,2
1School of Health and Life Sciences, Glasgow Caledonian University, Scotland, UK.
Insights
Patients with decompensated cirrhosis due to hepatitis C virus (HCV) significantly increased hospital admissions and stays between 1996-2013. This highlights a growing burden on healthcare resources from HCV-related liver disease and comorbidities.
Area of Science:
- Hepatology
- Infectious Diseases
- Health Services Research
Background:
- Hepatitis C virus (HCV) infection can lead to decompensated cirrhosis (DC), a severe stage with limited existing estimates of inpatient resource utilization.
- Understanding the healthcare burden is crucial for managing patients with advanced HCV-related liver disease.
Purpose of the Study:
- To quantify the inpatient hospital resource burden over time for patients with HCV and DC.
- To analyze trends in hospital admissions and length of stay for this patient population.
Main Methods:
- Retrospective longitudinal study using linked national HCV diagnosis and hospitalisation data in Scotland (1996-2013).
- Analysis of first DC admission, cumulative length of hospital stay, discharge diagnoses, and admission rates.
- Follow-up until May 2014.
Main Results:
- A 16-fold increase in annual admissions and an 11-fold increase in total hospital stay were observed between 1996 and 2013.
- DC patients (n=1312) had an average of 43 hospital days per person-year, with 26 days in the first 6 months post-admission.
- Admissions were predominantly for DC and other liver-related conditions, but non-liver comorbidities also contributed significantly.
Conclusions:
- HCV-infected DC patients represent a substantial inpatient hospital burden.
- The findings are essential for monitoring HCV prevention and treatment impacts and assessing the cost-effectiveness of new therapies.
Background & Aims:
To describe the burden on inpatient hospital resources over time from patients diagnosed with hepatitis C virus (HCV) infection and who have reached the decompensated stage of cirrhosis (DC), as existing estimates of hospital stay in these patients are limited.
Methods:
A retrospective longitudinal dataset was formed via record-linkage between the national HCV diagnosis database and inpatient/daycase hospitalisation and death registers in Scotland. The study population consisted of HCV-diagnosed patients with a first DC admission in 1996-2013, with follow-up available until 31 May 2014. We investigated and quantified the mean cumulative length of hospital stay, distributions over discharge diagnosis categories, and trends in admission rates.
Results:
Among our study population (n = 1543), we identified 10 179 admissions with any diagnosis post-first DC admission. Between 1996 and 2013 there was a 16-fold rise in annual total admissions (from 112 to 1791) and an 11-fold rise in hospital stay (719-8045). When restricting minimum possible follow-up to 2 years, DC patients (n = 1312) had an overall admission rate of 7.3 per person-year, and spent on average 43 days (26 days during first 6 months) in hospital; for all liver-related, liver-related other than HCC/DC, and non-liver related only admissions, this was 39, 14, and 5 days respectively.
Conclusions:
HCV-infected DC patients impose a considerable inpatient hospital burden, mostly from DC- and other liver-related admissions, but also from admissions associated with non-liver comorbidities. Estimates will be useful for monitoring the impact of prevention and treatment, and for computing the cost-effectiveness of new therapies.
Related Concept Videos
Hospitals-II
Nurses that work in...
Hospitals-I
Diagnosing Acidosis and Alkalosis
First, the pH level is assessed to determine whether the blood pH is normal (7.35–7.45), low (acidosis), or high (alkalosis).
Next, the PCO2 and...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

